Goodbye PCOS, Hello PMOS: Why the Name Change Matters for Every Woman

For 90 years, we've called it polycystic ovary syndrome. The problem? The name was wrong. This month, 56 global organizations voted to change it—and the shift could transform how millions of women are diagnosed and treated.

Imagine being told you have a condition. You're given a name for what's happening to your body. But that name is wrong. It focuses on a symptom that isn't even required for diagnosis. It hides the real risks—the diabetes, the heart disease, the mental health struggles. And it leaves you confused, dismissed, and searching for answers that your doctor can't give because they're working from the same flawed script.

For 90 years, that's been the reality for the 170 million women worldwide living with what we've called polycystic ovary syndrome .

But not anymore.

May 12, 2026 will go down as a landmark date in women's health history. That's the day The Lancet published the results of a 14-year global consensus process involving 56 academic, clinical, and patient organizations—and officially renamed PCOS to Polyendocrine Metabolic Ovarian Syndrome (PMOS) .

This isn't just a rebrand. It's a medical revolution wrapped in a name change.

For decades, the term "PCOS" has been what experts call a "misnomer." It implies pathological ovarian cysts—but the "cysts" seen on ultrasound are actually arrested follicles, not true cysts . The name made it sound like an isolated reproductive problem when the condition is actually a whole-body endocrine and metabolic disorder affecting everything from your pancreas to your heart to your mental health .

The consequences of this naming error have been devastating. Up to 70% of affected individuals remain undiagnosed . Those who are diagnosed often wait years—sometimes decades. And many are told: "Come back when you want to have children" .

This post is about why the name change matters. For the 1 in 8 women affected. For the doctors who treat them. And for anyone who believes that women's health deserves the same scientific precision as every other branch of medicine .

What Was Wrong With the Old Name?

Let me break this down. The old name, polycystic ovary syndrome, was problematic on multiple levels :

1. It was factually inaccurate.
The "cysts" in PCOS aren't actually cysts. On ultrasound, what appears as "cysts" are immature follicles—eggs that started developing but got stuck. They're not pathological, they're not dangerous, and they don't require surgery. But the name "polycystic" sent countless women into unnecessary panic, assuming they had ovarian tumors .

2. It hid the real story.
PCOS was never primarily about ovaries. The core of the condition is insulin resistance, which affects up to 85% of affected individuals—including 75% of lean women . The condition involves:

• The pancreas (insulin production)

• The hypothalamus and pituitary (brain hormones)

• The adrenal glands (androgen production)

• The liver (fat processing, MASLD risk)

• The heart and blood vessels (cardiovascular disease)

• The brain (mental health, sleep apnea)

None of this was captured by "PCOS" .

3. It delayed diagnosis and caused dismissal.
Patients were told they couldn't have PCOS because they didn't have cysts on ultrasound. Clinicians focused only on fertility, ignoring the metabolic risks. Women waited an average of 2-5 years for a correct diagnosis . One Australian woman told the Daily Telegraph: "When I first went to the GP to tell her I hadn't had my period for months, I felt entirely dismissed" .

The New Name: Breaking It Down

So what does PMOS actually mean? Let's decode it :

"Polyendocrine"
This captures the reality that multiple hormonal systems are involved—not just the ovaries. The condition affects:

• The hypothalamic-pituitary-ovarian axis (reproductive hormones)

• Adrenal androgen production (excess male hormones)

• Pancreatic insulin signaling (the metabolic driver)

• Adipokine signaling from fat tissue

• Gut hormones

The "poly" is crucial. This isn't one endocrine problem—it's several, interacting .

"Metabolic"
This is the most important addition. It puts insulin resistance front and center, where it belongs. The long-term risks of untreated PMOS are staggering:

• Diabetes risk: 4-5 times higher

• Heart attack risk: 2.5 times higher

• Stroke risk: 71% higher

• Metabolic dysfunction-associated steatotic liver disease (MASLD): 3 times higher risk

• Obstructive sleep apnea: 30-40% of women affected

The old name hid these risks. The new name demands that we address them .

"Ovarian Syndrome"
The name retains "ovarian" because the ovaries are still involved. But it's no longer the sole focus. The ovaries are affected by the endocrine and metabolic dysfunction—not the cause of it. As one expert put it, "The ovary is the victim, not the villain" .

What This Changes for Women

The name change isn't just symbolic. It has real, practical implications :

1. Earlier diagnosis.
Women no longer need to have "cysts" on ultrasound to be diagnosed. For adults, diagnosis can be based on clinical signs (irregular periods, excess hair growth, blood tests showing high androgens) and metabolic markers . The Royal Australian College of GPs has stated that ultrasound is no longer required for most women .

2. Whole-person care.
The new name forces clinicians to look beyond reproduction. Every woman diagnosed with PMOS should receive a complete cardiometabolic workup:

• Fasting insulin and glucose (HOMA-IR calculation)

• Full lipid panel

• Liver function tests

• Blood pressure monitoring at every visit

• Sleep apnea screening

• Regular glucose tolerance tests 

3. Reduced stigma.
"The way we name things has such important ramifications... in how patients view it and how other clinicians view it, but it also has everything in the world to do with research, and how that disorder gets funded and not funded," said Dr Sameena Rahman, an OB/GYN and certified menopause practitioner .

4. Better research.
With a clear, accurate definition, researchers can properly study subtypes, treatments, and long-term outcomes. Fertility specialist Dr Simon MacDowell called the change "well overdue," noting that PMOS includes "a variety of different subgroups" that can now be studied more carefully .

Real Life Story:

I think about the women who spent years being told their symptoms were "just stress" or "normal periods." Who were sent away with birth control pills and told to come back when they wanted to get pregnant. Who developed diabetes or heart disease before anyone connected the dots.

I think about Rochelle Lewis, diagnosed with PCOS at age 31 after years of symptoms. She was told it could affect her chances of becoming a mother—"absolutely devastating" for someone who had always wanted children. She now hopes the name change will "open the door" to more women being diagnosed quickly .

I think about Hannah Bambra, who waited five years for a diagnosis. She didn't have ovarian cysts, so doctors dismissed her. "I felt entirely dismissed," she told the Daily Telegraph. The new name, she says, "is really important for recognising this as a lifelong and whole body condition" .

I think about Rochelle Lewis again, who set up her own wellness business after her diagnosis. "When you have an idea of your life and how it's going to pan out from a little girl, to then be told 'actually, the one thing that you want most is most likely not going to happen'—it's absolutely devastating" .

And I think about Shireen Forster, diagnosed at 18, who went on to start a laser hair removal clinic after experiencing excessive hair growth herself. "This is not just cysts in women's ovaries," she says. "This is your metabolic—the way your body produces energy. This is your endocrine system... it's all these things linked" .

These women are why the name change matters. Their stories—of dismissal, frustration, and finally being heard—are the reason 56 organizations came together to make this happen.

The 14-Year Journey to Change

This didn't happen overnight. The name change was the result of a 14-year effort led by Professor Helena Teede, Director of the Monash Centre for Health Research and Implementation in Melbourne .

The process involved:

• Over 22,000 survey responses from patients and clinicians across all world regions

• 56 leading academic, clinical, and patient organizations

• Iterative Delphi surveys, workshops, and implementation analyses

• Patient advocates like Rachel Morman, chair of the UK charity Verity, who helped ensure the patient voice was central 

The new name was selected based on clear principles: scientific accuracy, stigma avoidance, cultural appropriateness, and implementation feasibility .

What Happens Now?

The transition to PMOS will happen over three years, with a managed implementation strategy :

• Year 1 (2026-2027): Publication, academic dissemination, resource development, and education campaigns

• Year 2 (2027-2028): Integration into electronic health records, health information systems, and provider training

• Year 3 (2028): Official integration into the International PMOS Guideline and eventual ICD reclassification

But clinicians are already changing their approach. Dr Magdalena Simonis from the Royal Australian College of General Practitioners says she's "really empowered now to make a diagnosis" without relying on ultrasound .

The Aprés Connection: Supporting Women Through the Journey

At Just Between Us, we've seen how conditions like PCOS (now PMOS) affect women's daily lives. The hormonal imbalances can lead to irregular bleeding, fertility challenges, and intimate discomfort. Many women with PMOS undergo fertility treatments—including vaginal progesterone pessaries—that leave behind messy residue.

Aprés was designed for post-intimacy cleanup. But women have discovered it helps with so much more: managing heavy flow from irregular periods, absorbing the aftermath of fertility treatments, and feeling clean and dignified when your body feels out of control.

The name change to PMOS is a reminder: women's health is whole-body health. And at Just Between Us, we're committed to addressing every part of it—from the endocrine system to the simple dignity of feeling clean.

Your Top Questions Answered!

1. "Do I have to stop using the term PCOS?"
Not immediately. The transition is happening over three years, and both terms will be used during that time. But the medical community is moving toward PMOS, and patients are encouraged to adopt it .

2. "I don't have ovarian cysts. Can I still have PMOS?"
Absolutely. Ovarian "cysts" are not a required feature of the condition. In fact, many women with PMOS don't show the classic "string of pearls" appearance on ultrasound. Diagnosis can be made based on clinical signs and blood tests alone .

3. "What are the biggest health risks I should know about?"
The metabolic risks are significant: type 2 diabetes, cardiovascular disease, stroke, and fatty liver disease. These risks persist even in lean women with PMOS. That's why the name change is so important—it forces these risks into the conversation .

4. "Does this change how PMOS is treated?"
Yes, in two important ways. First, treatment now focuses on insulin resistance as the root cause. Not just managing periods or fertility. Second, care should involve multiple specialists (endocrinology, cardiology, mental health), not just gynecology .

Your 4-Step Guide to Navigating the PMOS Transition

1. Ask your doctor about the new name. If you've been diagnosed with PCOS, ask: "Does the new PMOS name change how we should be managing my condition?" This opens the door to discussing metabolic health, not just reproduction.

2. Get your metabolic workup. If you have PMOS, ask for fasting insulin, glucose, HOMA-IR, a full lipid panel, liver function tests, and blood pressure monitoring. These should be standard .

3. Advocate for whole-body care. PMOS isn't just a gynecological condition. Ask for referrals to endocrinology, cardiology, and mental health support as needed.

4. Equip your daily life. While you're managing the big picture, don't forget the small things. Aprés can help with fertility treatment aftermath, heavy flow, and the simple desire to feel clean and comfortable in your body.

Key Takeaways:

1. On May 12, 2026, PCOS was officially renamed Polyendocrine Metabolic Ovarian Syndrome (PMOS) after a 14-year global consensus process .

2. The old name was misleading—it implied ovarian cysts and hid the condition's true nature as a whole-body endocrine and metabolic disorder .

3. PMOS affects more than 170 million women worldwide—approximately 1 in 8 women .

4. The condition involves insulin resistance (up to 85% of affected individuals), which drives metabolic and reproductive symptoms .

5. Untreated PMOS significantly increases risks for type 2 diabetes, heart attack (2.5x), stroke (71% higher), and fatty liver disease .

6. Up to 70% of affected individuals remain undiagnosed, with average diagnosis delays of 2-5 years .

7. The new name will be implemented over three years, with full integration into international guidelines by 2028 .

8. Diagnosis no longer requires ultrasound evidence of ovarian "cysts"—clinical signs and blood tests are sufficient .

9. The change is expected to improve research funding, patient advocacy, and access to appropriate care .

10. For women managing PMOS-related fertility treatments, irregular bleeding, or heavy flow, Aprés offers dignified, gentle support.

Did you know PCOS has a new name? PMOS 'Polyendocrine Metabolic Ovarian Syndrome' better reflects the whole-body nature of a condition affecting 1 in 8 women. While the medical world catches up, you deserve tools that support your daily comfort. Whether that's managing fertility treatment aftermath, heavy flow, or simply feeling clean in your body. Subscribe to Just Between Us for more honest conversations about women's health.